Summary
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
History
Aldeyra Therapeutics, Inc. was founded in 2011 and is headquartered in Lexington, Massachusetts. The company raised $35 million in a 2017 initial public offering and is publicly traded on the NASDAQ.
Mission
Our mission is to bring innovative therapies to patients with diseases related to free radical chemistry imbalance.
Vision
Our vision is to develop, manufacture and market products that will improve the quality of life for people suffering from these diseases.
Key Team
Mr. Kelly Mizer (VP of Commercial Strategy & Operations)
Recognition and Awards
Aldeyra Therapeutics has received awards from the Financial Times, Boston Business Journal, and the National Institutes of Health, among others.
References
United States 